Risk of ICI-associated myocarditis is higher when anti-CTLA-4 therapy is combined with anti-PD-L1 therapy than with anti-PD-L1 monotherapy [72], and risk may be elevated for patients with autoimmune disease and diabetes mellitus. This evidence concerns the gene CD274 and myocarditis.